Alkaptonuria (AKU)

AKU, also known as Black Bone Disease, is an ultra-rare genetic metabolic disorder that affects around one in 250,000 to 1,000,000 people in the US.1

AKU is caused by mutations in the homogentisate 1,2-dioxygenase (HGD) gene, an enzyme involved in the breakdown of the amino acid tyrosine.1 Under normal conditions, HGD converts homogentisic acid (HGA) into maleylacetoacetic acid as part of the tyrosine degradation pathway. In individuals with AKU, mutations in HGD disrupt this process, leading to a buildup of HGA in the blood and tissues. As a result, HGA levels can rise up to 2,000 times above normal,2 causing ochronosis (discoloration in skin and cartilage) and early-onset arthritis, among other symptoms that typically become more apparent after the age of 30.1

Given how rare the condition is, its slow progression, and variable presentation, AKU diagnosis is challenging. From birth, dark urine and dark-stained diapers are noticeable signs of AKU, but are easily missed if the urine has not had time to oxidize. Other clinical symptoms are often mistaken for other types of arthritis or skin conditions.1

Over time, patients’ quality of life deteriorates due to developed pain and loss of joint mobility.1,4 While AKU does not seem to affect life expectancy, it can increase the risk of fractures, kidney stones, and heart complications.1,3

Assessing patients for AKU

AKU should be considered and ruled out for all patients with black urine and early onset osteoarthritis.5 A urine sample can be taken to determine if HGA levels are high, which is usually indicative of AKU.1

Do you have a patient with suspected AKU?

Learn about HARLIKU™ (nitisinone) TabletsDiscover dedicated support for AKU

References

1. Introne WJ, Perry M, Chen M. 2003 (updated 2021). Alkaptonuria. Available at: https://www.ncbi.nlm.nih.gov/sites/books/NBK1454/ [Accessed: May 29 2025].
2. AKU Society. Information for Healthcare Professionals. Available at: https://akusociety.org/for-healthcare-professionals/ [Accessed: May 1 2025].
3. Zatkova, A., Ranganath, L., & Kadasi, L. 2020. Alkaptonuria: Current Perspectives. The application of clinical genetics, 13, 37–47. doi:10.2147/TACG.S186773
4. AKU Society. Symptoms. Available at: https://akusociety.org/symptoms/ [Accessed: May 1 2025].
5. AKU Society. Diagnosis. Available at: https://akusociety.org/diagnosis/ https://akusociety.org/symptoms/ [Accessed: May 8 2025].

HALIKU Logo
HALIKU Logo

Indications

HARLIKU™ is indicated for the reduction of urine homogentisic acid (HGA) in adult patients with alkaptonuria (AKU).

Important Safety Information

Do not prescribe HARLIKU to patients allergic to nitisinone or any other contained ingredients.

Warnings and Precautions:

Ocular Symptoms and Hyperkeratotic Plaques Due to Elevated Plasma Tyrosine Level:

Ocular signs and symptoms including keratitis, corneal opacities, corneal irritation, corneal ulcers, conjunctivitis, eye pain, and photophobia, have all been reported in patients treated with nitisinone.

    • Perform slit-lamp examination prior to treatment and regularly thereafter. Reexamine patients if symptoms develop or tyrosine levels are > 500 micromole/L. Assess plasma tyrosine levels in patients with an abrupt change in neurological status.
    • Perform a clinical laboratory assessment, including plasma tyrosine levels, in patients with an abrupt change in neurological status.

Leukopenia and Severe Thrombocytopenia

In clinical trials, patients with hereditary tyrosinemia type 1 (HT-1) treated with another oral formulation of nitisinone and dietary restriction developed reversible leukopenia (3%), thrombocytopenia (3%), or both (1.5%). No patients developed infections or bleeding as a result of the episodes of leukopenia and thrombocytopenia. Monitor platelet and white blood cell counts during HARLIKU therapy.

There is no routine dietary restriction requirement for AKU patients taking HARLIKU. Implement diet restriction and/or treatment interruption as appropriate.

Adverse Reactions:

The most common adverse reactions (≥1%) reported in patients with AKU taking nitisinone in clinical trials are elevated tyrosine levels, thrombocytopenia and keratitis including eye irritation, eye pain and photophobia.

Drug Interactions:

    • Nitisinone is a moderate CYP2C9 inhibitor and a weak CYP2E1 inducer. Potential clinical impact of nitisinone administration with CYP2C9 substrates. Reduce the dosage of the co-administered drugs metabolized by CYP2C9 by half. Additional dosage adjustments may be needed to maintain therapeutic drug concentrations where minimal concentration changes may lead to serious adverse reactions.
    • Nitisinone is an inhibitor of OAT1/OAT3. Potential clinical impact of administration with OAT1/OAT3 substrates. Patients should be monitored for potential adverse reactions.

Use in Specific Populations:

Pregnancy: Limited available data with nitisinone use in pregnant women are not sufficient to determine a drug-associated risk of adverse developmental outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.

Lactation: The developmental and health benefits of breastfeeding should be considered against the mother’s clinical need for HARLIKU, along with any potential adverse effects on the breastfed infant from HARLIKU or from the underlying maternal condition.

Pediatric Use: The safety and effectiveness of HARLIKU have not been established in pediatric patients with AKU.

Geriatric Use: Insufficient data from clinical studies of HARLIKU to determine if patients ≥ 65 years of age respond differently. Elderly patients should be cautious reflecting any decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

For more detailed information, please refer to the full Prescribing Information at harliku.com/pi/

To report SUSPECTED ADVERSE REACTIONS, contact Cycle Pharmaceuticals at 1-855-831-5413, or the FDA at: 1-800-FDA-1088 or www.fda.gov/medwatch.

HARLIKU™ (nitisinone) Tablets

© 2026 Cycle Pharmaceuticals Limited. All rights reserved.

HARLIKU™ and Cycle Vita™ are trademarks of Cycle Pharmaceuticals Limited in the United States.

Contact us

@CycleVitaUSA

@CycleVitaUSA